Platinum Investment Management Ltd. Sells 50,274 Shares of Roivant Sciences Ltd. $ROIV

Platinum Investment Management Ltd. trimmed its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 21.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 189,146 shares of the company’s stock after selling 50,274 shares during the quarter. Platinum Investment Management Ltd.’s holdings in Roivant Sciences were worth $4,104,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. SBI Securities Co. Ltd. increased its position in shares of Roivant Sciences by 1,740.3% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after buying an additional 1,166 shares during the period. Jones Financial Companies Lllp increased its position in shares of Roivant Sciences by 226.0% during the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock worth $25,000 after buying an additional 1,148 shares during the period. Allworth Financial LP increased its position in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after buying an additional 583 shares during the period. Bessemer Group Inc. increased its position in shares of Roivant Sciences by 41.5% during the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock worth $28,000 after buying an additional 543 shares during the period. Finally, CIBC Private Wealth Group LLC increased its position in shares of Roivant Sciences by 7,614.3% during the fourth quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock worth $59,000 after buying an additional 2,665 shares during the period. 64.76% of the stock is owned by institutional investors.

Analyst Ratings Changes

ROIV has been the subject of several recent analyst reports. Jefferies Financial Group reiterated a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. HC Wainwright reiterated a “buy” rating and set a $34.00 price objective on shares of Roivant Sciences in a research report on Thursday, May 21st. Guggenheim increased their price objective on shares of Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. Weiss Ratings downgraded Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Finally, Leerink Partners set a $42.00 target price on Roivant Sciences in a report on Thursday, May 21st. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $33.59.

Insiders Place Their Bets

In other Roivant Sciences news, CAO Jennifer Humes sold 13,538 shares of Roivant Sciences stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $28.37, for a total value of $384,073.06. Following the completion of the sale, the chief accounting officer directly owned 84,191 shares in the company, valued at approximately $2,388,498.67. The trade was a 13.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Melissa B. Epperly sold 41,861 shares of Roivant Sciences stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $28.68, for a total value of $1,200,573.48. Following the completion of the sale, the director owned 15,804 shares of the company’s stock, valued at approximately $453,258.72. The trade was a 72.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 945,173 shares of company stock valued at $27,654,456. Company insiders own 10.80% of the company’s stock.

Roivant Sciences Stock Performance

Shares of ROIV stock opened at $30.04 on Friday. The company has a market cap of $21.61 billion, a P/E ratio of -50.07 and a beta of 1.13. The stock has a 50 day simple moving average of $28.95 and a two-hundred day simple moving average of $25.98. Roivant Sciences Ltd. has a fifty-two week low of $10.70 and a fifty-two week high of $32.79.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.57. The business had revenue of $2.52 million during the quarter, compared to the consensus estimate of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same period in the previous year, the company posted ($0.29) earnings per share. On average, research analysts predict that Roivant Sciences Ltd. will post -1.83 earnings per share for the current year.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.